Pulmonary vascular disease & thromboembolism
Tricuspid Annular Plane Systolic Excursion (TAPSE)/Systolic Pulmonary Artery Pressure (sPAP) Ratio to Improve Risk Assessment in Pulmonary Arterial Hypertension
Authors' conclusion
Assessment of right ventricular-PA coupling by the TAPSE/sPAP ratio in PAH improves risk assessment scores except in the lowest or most advanced stage of the disease.
Study context
- Population
- Patients with pulmonary arterial hypertension (PAH) on targeted therapies, 55% idiopathic
- Participants
- 677 vs 254
- Exposure
- PAH vs Validation
- PAHn = 677
- Validationn = 254
- Outcome
- Low-risk status (ESC/ERS and REVEAL 2.0 risk scores) by TAPSE/sPAP ratio
- Follow-up
- Median 3.7 years (IQR, 1.2-6.8)
Methodological detailsmulticentre, 11 Italian centres, external validation cohort
- Multicentre
- 11 Italian centres
- External validation cohort
Main finding
As reported in the abstract
Low-risk status per 0.1 mm/mm Hg increase in TAPSE/sPAP · median 3.7 years follow-up
Odds ratio
1.78
P ≤ 0.001
ESC/ERS score
Odds ratio
1.43
P ≤ 0.001
REVEAL 2.0 score
Observational data: associations, not effects.
Further findings
Added prognostic information of TAPSE/sPAP to ESC/ERS risk strata · follow-up
- Increased prognostic information in each stratum except the highest; best cutoffs from lowest to intermediate-high risk
- 0.5 mm/mm Hg, 0.35 mm/mm Hg, 0.30 mm/mm Hg
Added prognostic information of TAPSE/sPAP to REVEAL 2.0 score · follow-up
- Best cutoff to discriminate within a score of 5 to 8; no added value for scores <5 and >8
- 0.35 mm/mm Hg
Validation cohort
- Results confirmed in the validation cohort
Original publication
TAPSE/sPAP Ratio to Improve Risk Assessment in Pulmonary Arterial Hypertension. Circ Heart Fail. Published 17 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →